Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Conditions: Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Large Cell Lymphoma; Refractory Childhood Acute Lymphoblastic Leukemia; Refractory Childhood Hodgkin Lymphoma; Refractory Childhood Malignant Ger m Cell Neoplasm; Recurrent Childhood Brain Tumor; Recurrent Childhood Brainstem Glioma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Childhood Ependymoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childh ood Gliosarcoma; Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Refractory Childhood Malignant Solid Neoplasm; Recurrent Childhood Malignant Solid Neoplasm; Recurrent Childhood Malignant Neoplasm; Refractory Childhood Malignant Neoplasm Intervention: Sponsors: Florida International University; Nicklaus Children's Hospital f/k/a Miami Children's Hospital; First Ascent Biomedical, Inc.; National Institute on Minority Health and Health Disparities (NIMHD) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Brain Tumor | Cancer & Oncology | Children | Chronic Leukemia | Chronic Myeloid Leukaemia | Ependymoma | Glioma | Hospitals | Leukemia | Lymphoma | Research | Rhabdomyosarcoma | Sarcomas